Addition of venetoclax to azacytidine improves outcomes for subset of patients with AML

“We know that poor-risk cytogenetics are associated with worse outcomes in patients treated with conventional therapies. We also know that TP53 mutations frequently co-occur with poor-risk cytogenetics…,” Daniel A. Pollyea, clinical director of leukemia services, associate professor of medicine and hematology and Robert H. Allen MD chair in hematology research at University of Colorado Anschutz Medical School, told Healio.